hypotensive anesthesia
Download
Report
Transcript hypotensive anesthesia
PRESENTED BY: Dr CHITTRA
MODERATED BY: Dr GIRISH
Concept of intentional induction of hypotension to
decrease blood loss was first proposed by Cushing in
1917
Use of circulatory adjustments to achieve desirable
hemodynamic state in order to decrease blood loss
associated with surgery
Controlled lowering of arterial blood pressure
Light anesthesia
Coughing, bucking, airway obstruction, PEEP, improper
positioning, fluid overload - ↑central venous pressure
General vs regional
Posture : parts above heart are perfused at lower pressures
For every 1 inch of vertical height 2mmHg decrease in
pressure
Head –up tilt favours arterial hypotension in upper parts
Positioning of surgery above the heart improves
drainage of blood and local tissue flow
Dec venous and capillary bleeding
Maintain low intrapulmonary pressure during
controlled ventilation
Tourniquiet application-pressure 100mm above
systolic… 1.30hrs max allowable time
i.v. line and basic monitoring should be established
Invasive BP monitoring is must
After intubation controlled ventilation is preferred
Hypotension is induced gradually by hypotensive drug
given at least 10 min before surgery commences
Patient is then tilted to decrease arterial pressure
Further decrease in arterial pressure can be obtained by
gradual increase in anesthestic conc
Further dec will be done by hypotensive drugs
HALOTHANE:
Dose dependent depression of myocardial contractility
more pronounced myocardial depression in ischemic
myocardium
Do not alter diastolic fxn
decreases LV mechanical efficiency
attenuates baroreceptor reflex responses
Decreases in arterial pressure produced by halothane
are attributed to reductions in myocardial contractility
and cardiac output, there is no change in SVR
It is a potent cerebral vasodilator
Cerebral blood flow and volume are inc
At more than 1 MAC obtunds cerebrovascular
vasoconstriction in response to hypocapnia
Elective hypocapnia is used to dec cerebral blood
flow,ICP during neurosurgery. Hence CI in these
surgeries
ISOFLURANE:
More rapid induction of hypotension, easy control
and prompt recovery
Incerased HR, CO and Stroke volume are
maintained upto MAC×2
Dec in SVR
Direct acting myocardial depression also happens
but at MAC× 2.5
In presence of moderate reduction of PaCo2 3035mmhgCMRO2 is decreased and cerebral blood
flow is unchanged despite decrease in cerebral
vascular resistance
At more than 1 MAC vasodilatory effects become
prominent
Reduction in CO or decrease in SVR
Precapillary arterioles are major determinants of resistance
CLASSIFICATION:
GANGLIONIC BLOCKERS: pentolinium, trimethaphan
DIRECT ACTING VASODILATORS: SNP,NTG,Hydralazine ,
adenosine, PGE1
α- ADRENERGIC BLOCKING DRUGS: phentolamine,
urapidil,nicergoline
Β-ADRENERGIC BLOCKING DRUGS: propranolol,esmolol
α+β BLOCKING DRUGS: Labetalol
CALCIUM CHANNEL BLOCKERS: Verapamil, nifedipine
Compete with Ach for nicotinic receptors on autonomic
postjunctional ganglionic membrane
Overall effect of autonomic blockade depends on
predominance of one or other system
Produces vasodilation, ↑ed venous capacitance and
hypotension
Mainly acts through NO
NO diffuses into vascular smooth muscle , stimulates c-
GMP ,causing vascular relaxation
SNP and NTG provide exogenous NO
SODIUM NITROPRUSSIDE
NITROGLYCERINE
Onset of
action
Rapid onset, rapid recovery
Rapid , moderately slow recovery
Duration
Evanescent action
Short acting
Route
i.v. drip
i.v. drip
Mode of action Direct effect on both resistance
and capacitance vessels
Direct effect on capacitance
vessels mainly
Tachycardia
May occur in children
Very common
Cardiac output Unchanged,↑,↓,depending on
posture preload,afterload,other
depressant drugs
,
Metabolism
Cynaide and thiocyanate
Degraded rapidly
Stability
Available as powder,unstable
when reconstituted,protect from
light,use within 12 hrs
Stable,colorless,absorbed by
plastics,use high density
polyethylene drips
Dose
0.5-10µ/kg/min
0.5-10µ/kg/min
ICP
↑ in early stages
↑
Rebound HTN
Occurs in absence of β blockade
Does not occur
CYANIDE TOXICITY
Molecular formula of SNP Na2{Fe(CN5)NO}×2H2O
Cyanide released from SNP is transformed into nontoxic
products
Disposal of free CNˉ through:
1. Conversion to cyanomethemoglobin: 1 of every 5 CNˉ ions
is converted
2. Binding to cytochrome oxidase: inhibiting oxidative
phosphorylation
3. Conversion to cyanocobalamin: in presence of adequate
hydroxocobalamin
4. Conversion to thiocyanate: catalyzed by enzyme
rhodenase
Mechanism of cyanide toxicity is interference with
aerobic metabolism
Free CNˉinhibits electron transport system
Decreased oxygen utilisation, decreased CO2
production, increased production of anaerobic
metabolites
Metabolic acidosis and deterioration of CNS and CVS
occurs
HALLMARK of cytotoxic hypoxia is tissue hypoxia
with normal or elevated PaCO2
DETECTION OF CYANIDE TOXICITY:
Impending CNˉ intoxication
a. Requirement for high doses of SNP >10µg/kg/min
b. Resistance apparent within 5-10 min after start of
infusion
c. Tachyphylaxis apparent 30-60/min after start of
infusion
Severity of acidosis proportional to CNˉ level
Lethal blood CNˉ level in humans is 500µg/dl
Lethal blood thiocyanate level is 340µg/dl
Increased requirements of SNP
Metabolic acidosis
Progressive hypotension with narrow pulse pressure
Refractory hypotension unresponsive to vasopressors
and fluids ,responsive to thiosulfate
CVS collapse
Bright venous blood
Increased SpO2 and PaO2
Total projected dose should not exceed 1.5mg/kg for
short duration or 0.5mg/kg/hr for long duration
Infusion rate should not exceed 10µ/kg/min
Initial rate should be 0.5-1µ/kg/min
Frequent arterial acid base determinations should be
done
Antidote therapy should be available
If high dose is needed other drugs should be added
If still resistance is detected infusion should be
abandoned
Sodium thiosulfate is DOC
3 times more than CNˉ should be present
Provides adequate supply of sulfhydryl radicals to form
thiocyanate from CN ˉ
Bolus inj of 30mg/kg ,cont infusion of 60 mg/kg/h
Hydroxycobalamin (vit B12) prevents inc in CNˉ conc
in RBC’s when given with SNP
50mg/kg bolus,infusion 100mg/kg/h
Acidosis correction and fluid replacement
Endogenous vasodilator
Acts on specific adenosine receptors located in several
vascular beds and on AV node
Activation of adenylate cyclase and depression of action
potentials
Selectively affects resistance vessels, with little effect on
venous capacitance
Because of very short half-life (< 10 s), continuous
infusion (60–120 g/kg/min) is required for controlled
hypotension
Hypotension is short lasting, not accompanied by rebound
hypertension when discontinued
↑ coronary blood flow ,↓ afterload
Unfavorable changes in distribution of regional coronary
blood flow may led to myocardial ischemia in patients
with CAD
Inhibits renin release and prevents activation of RAS
Dilates cerebral vessels, ↑ ICP, impairs cerebral
autoregulation
Direct arteriolar vasodilator
↓ SVR ,no change in CO ,reflex tachycardia
↑ ICP but no rebound HTN
i.v. dose is 2.5 to 10 mg-effect begin within 10 to 20 minutes
and last 3 to 6 hours max dose 20 mg
Parenteral administration of hydralazine is not advisable in
patients with coronary artery disease, patients with multiple
cardiovascular risk factors, or in older patients of possibility of
precipitation of myocardial ischemia due to reflex tachycardia
FENOLDOPAM
Pure D1 antagonist with selective renal , mesentric, &
peripheral vasodilator action
Maximal response in 10-20 min
Cont infusion 0.1- 0.6µg/kg/min
Potent vasodilator effect on pulmonary and systemic
vascular beds
100-150ng/kg/min used to induce hypotension
BP returns to 15% of normal 15min after infusion is
stopped
↑ in plasma renin activity
Phentolamine produces transient nonselective α-
adrenergic blockade
Administered intravenously, phentolamine produces
peripheral vasodilation and decrease in systemic blood
pressure that manifests within 2 minutes and lasts 10
to 15 minutes
Decreases in blood pressure elicit baroreceptormediated increases in sympathetic nervous system
activity, manifesting as cardiac stimulation
30 to 70 µg/kg IV
Prevents ↑ in HR, CO, plasma renin activity,
catecholamine levels & blocks rebound HTN after
stoppage of SNP infusion
Esmolol is more effective than SNP in producing better
operative conditions
Rapid onset, short duration ,cardioselectivity
DRUG
DOSE
CARDIOSELEC
TIVITY
ELIMINATION
HALF- LIFE
PROPRANOL
OL
0.06mg/kg
0
4 hrs
Metoprolol
0.15mg/kg
+
3-4 hrs
Esmolol
Loading dose: 0.5
mg/kg/min,
0.3mg/kg/min infusion
+
10 min
Labetalol
0.2-0.4 mg/kg
0
3.5-4.5 hrs
LABETALOL
α1 , β1 , β2 blocker& partial agonist at β2 receptor,
inhibition of neuronal uptake of norepinephrine
Potency for β blockade is 1/5th to 1/10th of α blockade
With inhalation agents ↓es BP by decreasing SVR with
either no change or ↓ HR & slight or no ↓ in CO
Preferred when prolonged hypotension is required
Absence of tachycardia, ↑ in CO ,rebound HTN , ICP
bolus dose is 20 mg initially (over 2 min), followed by
20 to 80 mg every 10 minutes to total dose of 300 mg
Infusion rate is 0.5 to 2 mg/min
Verapamil and nicardipine decreases SVR
Verapamil produces myocardial depression and delays AV
conduction- not recommended for induced hypotension
Nicardipine vasodilates peripheral, coronary, cerebral
vessels while maintaining CO without tachycardia
The peripheral vasodilation and resulting decrease in
systemic blood pressure produced by nifedipine activate
baroreceptors, leading to increased peripheral sympathetic
nervous system activity manifesting as increased heart rate
This increased sympathetic nervous system activity
counters the direct negative inotropic, chronotropic, and
dromotropic effects of nifedipine.
Use of inhalational anesthetics
Avoid fluid overload
Preop sedation and opioids
Use of β blockers
Adequate analgesia and muscle relaxation
Pretreatment with ACE inhibitors
Combining drugs/dexmedetomidine /clonidine
ONSET AND DEGREE OF HYPOTENSION:
Hypotension should be induced slowly within 10-15
min
BP should not be lowered to predetermined level
Depends on age,condition, posture, surgical
requirement
Very dry operative field and dark venous blood reqires
increase in BP
Central venous oxygen tension below 30 mmHg
indicates tissue hypoxia
Near normal PaCo2 should be maintained
Hypocapnia decreases CO, coronary, cerebral and spinal
cord blood flows ,cause leftward shift of oxyhemoglobin
dissociation curve, inhibit HPV
Increase in alveolar dead space is of significance only in
elderly patients or when both PEEP and head up tilt are
used
Increase in diff b/w alveolar and arterial oxygen tensions
{P (A-a)O2}
Increased intrapulmonary shunt
Blunting of HPV reflex is seen with inhalation
anesthetics and vasodilators
More with SNP than with NTG
Decrease in PVR and pulmonary artery pressure
,increased shunt fraction
Decrease CO
Increased extraction of oxygen by tissues
Portion of blood with decreased mixed venous
oxygenation that passes through hypoventilated areas
have more dec in PaO2
High FiO2 is recommended
Compensates for venous admixture due to V-Q
imbalance
RELATIVE CONTRAINDICATIONS
Inexperience
Pregnancy
Significant reduction in oxygen delivery
Renal,cerebral or CAD
Children with cardiac shunts
Patients with sickle cell disease
Uncorrected polycythemia
Ganglionic blocking drugs in patients with narrow
angle glaucoma
Cardiac arrest and hypotension
Temporary or permanent neurologic deficits
Reactionary hrg
Failure of technique